Online survey: Infant RSV monoclonal antibody device/container assessment [PATH]

[kareiv...@gmail.com]

Dear colleagues,

As you know, respiratory syncytial virus (RSV) is a common cause of childhood acute lower respiratory infection that leads to hospitalizations and deaths, particularly in children younger than 6 months. Product development efforts are underway to make available monoclonal antibody (mAb) products that protect infants from RSV. PATH is currently collecting feedback on the most appropriate container/device to administer one such RSV mAb product to infants. The goal of the project is to inform infant RSV mAb product development.

We would like to invite BLN members with expertise/experience in childhood immunizations to complete an online survey to provide input on selecting the most appropriate container/device to administer the RSV mAb product to infants. Also, please share the survey information with other colleagues who have expertise. The survey should take 10-20 minutes to complete and can be accessed through November 15, 2021 by clicking this link: RSV mAb stakeholder survey.

Your contributions are invaluable to this effort, and we look forward to learning from your insights! Thank you very much, in advance, for your time.

If the link above does not work, try copying this into your web browser: https://redcap.iths.org/surveys/?s=K7DJMCRWK4LLLFRL

Best regards on behalf of Dr. Manjari Quintanar Solares (MD, MPH) and the team,

Abra Greene

Project Coordinator

Medical Devices and Health Technologies Program

PATH